REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory ...

Chronic obstructive pulmonary disease (COPD) is a multi-faceted disease that is a major cause of morbidity and mortality worldwide, and is a significant burden in terms of healthcare resource ...

Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...

Mucolytic agents decrease mucus viscoelastic properties, improve mucociliary clearance and decrease sputum production and appear designed to provide symptomatic relief to mucus hypersecretion in COPD.

Results from a new report published in the British Journal of Clinical Pharmacology revealed that clinicians could be overprescribing opioids to older adults suffering from chronic obstructive ...

COPD breathlessness action plans may help patients manage episodes, reduce anxiety, and avoid emergency care. Read more.

The free sulfhydryl group of metabolite I breaks the disulfide bridges of mucus glycoproteins, resulting in reduced sputum physical properties in patients with acute and chronic mucus hypersecretion.

EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...